Keytruda in Jordan
How patients in Jordan access Keytruda (PD‑1 inhibitor) via Named Patient Program.
Keytruda - overview
Keytruda (PD‑1 inhibitor) is manufactured by Merck (MSD) and indicated for multiple oncology indications including melanoma, NSCLC, head and neck cancer, classical Hodgkin lymphoma, urothelial carcinoma, MSI-H/dMMR solid tumors, TMB-H solid tumors, renal cell carcinoma, endometrial carcinoma, triple-negative breast cancer, cervical cancer, gastric cancer, and others, see full prescribing information. It is an intravenous anti-PD-1 monoclonal antibody approved by the US FDA in 2014 and may be accessible to patients in Jordan through a Named Patient Program or personal-import pathway.
Access in Jordan
Jordan's JFDA operates a compassionate-use framework for unregistered drugs; requires physician and JFDA approval.
How Reserve Meds coordinates access in Jordan
- Patient or treating physician submits a request.
- We verify clinical appropriateness and Jordan-specific eligibility.
- Treating physician in Jordan issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Keytruda from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in Jordan.
Typical timeline for Jordan
End-to-end, most requests are completed in 2-6 weeks. Jordan's tier 2 regulatory maturity typically supports moderate processing times.
What patients and physicians in Jordan ask
- Is the pathway legal in Jordan? Yes - it operates under Jordan's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in Jordan able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.